Search International and National Patent Collections
|1. (WO2017151775) USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] FOR THE TREATMENT OF CANCER|
|Title:||USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] FOR THE TREATMENT OF CANCER|
IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.